related documents
- Long-term efficacy and safety of guselkumab in psoriasis patients with and without psoriatic arthritis: A pooled analysis from VOYAGE 1 and VOYAGE 2 Conferences
- Secukinumab demonstrates significant improvement of disease activity and health-related quality of life in Canadian psoriasis patients in a real-world setting Conferences
- Sociodemographic and baseline disease profile of patients with moderate to severe chronic plaque psoriasis treated with secukinumab vs. other treatments in Canadian routine clinical care: Results from the PURE registry Conferences